logo
Volt Group Limited's (ASX:VPR) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Volt Group Limited's (ASX:VPR) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Yahoo20 hours ago
Volt Group's (ASX:VPR) stock is up by a considerable 40% over the past three months. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health over the long-term usually dictates market outcomes. Specifically, we decided to study Volt Group's ROE in this article.
Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. Put another way, it reveals the company's success at turning shareholder investments into profits.
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
How Is ROE Calculated?
Return on equity can be calculated by using the formula:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
So, based on the above formula, the ROE for Volt Group is:
21% = AU$1.4m ÷ AU$6.5m (Based on the trailing twelve months to December 2024).
The 'return' is the amount earned after tax over the last twelve months. So, this means that for every A$1 of its shareholder's investments, the company generates a profit of A$0.21.
See our latest analysis for Volt Group
Why Is ROE Important For Earnings Growth?
Thus far, we have learned that ROE measures how efficiently a company is generating its profits. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
Volt Group's Earnings Growth And 21% ROE
To begin with, Volt Group seems to have a respectable ROE. On comparing with the average industry ROE of 12% the company's ROE looks pretty remarkable. Probably as a result of this, Volt Group was able to see an impressive net income growth of 60% over the last five years. We reckon that there could also be other factors at play here. For instance, the company has a low payout ratio or is being managed efficiently.
When you consider the fact that the industry earnings have shrunk at a rate of 0.9% in the same 5-year period, the company's net income growth is pretty remarkable.
Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is Volt Group fairly valued compared to other companies? These 3 valuation measures might help you decide.
Is Volt Group Efficiently Re-investing Its Profits?
Volt Group doesn't pay any regular dividends to its shareholders, meaning that the company has been reinvesting all of its profits into the business. This is likely what's driving the high earnings growth number discussed above.
Summary
On the whole, we feel that Volt Group's performance has been quite good. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. If the company continues to grow its earnings the way it has, that could have a positive impact on its share price given how earnings per share influence long-term share prices. Remember, the price of a stock is also dependent on the perceived risk. Therefore investors must keep themselves informed about the risks involved before investing in any company. To know the 3 risks we have identified for Volt Group visit our risks dashboard for free.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hansen secures a significant three-year contract extension with Africa's MultiChoice Group
Hansen secures a significant three-year contract extension with Africa's MultiChoice Group

Yahoo

time7 hours ago

  • Yahoo

Hansen secures a significant three-year contract extension with Africa's MultiChoice Group

MultiChoice will upgrade to the latest version of Hansen CCB and extend its managed services solutions agreement as it continues to navigate Africa's complex and diverse regional and country regulations. MELBOURNE, Australia, July 29, 2025--(BUSINESS WIRE)--Hansen Technologies (ASX:HSN), a leading global provider of software and services to the communications & media and energy & utilities industries, has signed a three-year contract renewal with MultiChoice Group to enable the continued utilisation of Hansen CCB, as well as the extension of the existing managed services solutions. The agreement, initially for a term of three years, combines various contracts into a single master contract; aligning to MultiChoice's ambition to transition to this latest version of Hansen CCB. MultiChoice is a South African company that operates DStv, a major satellite television service in Sub-Saharan Africa. As Africa's leading entertainment platform, MultiChoice offers a diverse range of content across multiple brands and countries. For over 25 years, MultiChoice has relied on Hansen for their single billing solution, which supports subscribers across 50 markets. Hansen's continued investment into the CCB platform has allowed MultiChoice to adeptly and efficiently handle the mission critical complexities of the various regional requirements and diverse country regulations across Africa. The extension of the contract is a reflection of MultiChoice's resounding confidence in Hansen, not only as a platform provider but as a partner in their evolving future. MultiChoice Group Chief Technology & Information Officer, Sabelo Mwali comments: "Hansen has proven to be an invaluable partner over many years, consistently providing software and services that have resulted in a highly flexible, reliable and efficient billing platform for the MultiChoice Group. "We look forward to continuing and expanding our highly successful collaboration with Hansen for many years to come." Hansen's President of Communications & Media, Scott Weir, shares: "This agreement re-iterates the confidence Tier-1 industry players hold in Hansen's technology and expertise to deliver mission-critical Billing solutions. "We look forward to the further extension of the long-standing relationship we have built over the years as we continue to support MultiChoice's ambitions of further innovation and investment into the entertainment arena in Africa." For further information about Hansen, please visit About Hansen Hansen Technologies (ASX: HSN) is a leading global provider of software and services to the energy & utilities and communications & media industries. With its award-winning software portfolio, Hansen serves organisations with customers located in over 80 countries, helping them to create, sell, and deliver new products and services, manage and analyse customer data, and control critical revenue management and customer support processes. For more information, visit About MultiChoice MultiChoice is Africa's leading entertainment platform, with a mission to enrich lives. The company offers a wide range of products and services, including DStv, GOtv, Showmax, M-Net, SuperSport, Irdeto, and KingMakers. Its products and services are used by over 23.5 million households in 50 markets across sub-Saharan Africa. View source version on Contacts For further information, please contact: Megan RosierDirector, Corporate Communications & Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Yahoo

time8 hours ago

  • Yahoo

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep' or 'the Company'), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial at the IASLC 2025 World Conference on Lung Cancer (WCLC), taking place in Barcelona, Spain, from 6-9 September 2025. The Trial in Progress poster includes an overview and study design of the TACTI-004 Phase III evaluating the Company's antigen presenting cell (APC) activator, eftilagimod alfa (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 KEYTRUDA® (pembrolizumab) and chemotherapy as first line therapy for patients with advanced or metastatic non-small cell lung cancer (1L NSCLC). The global trial will enrol approximately 750 patients regardless of PD-L1 expression (Tumour Proportion Score or TPS of 0-100%) and with non-squamous or squamous tumours at over 150 clinical sites in over 25 countries. Immutep CMO, Stephan Winckels M.D., Ph.D, said, 'Our engagement to date with physicians in the lung cancer community, including at ELCC in Paris and ASCO in Chicago, has yielded encouraging feedback with a shared view of efti as a safe, easy-to-administer immunotherapy with strong efficacy across two 1L NSCLC trials. We look forward to continuing our investigator discussions at WCLC and ESMO around the pivotal TACTI-004 Phase III, which has the potential to change the treatment paradigm for patients with advanced or metastatic non-small cell lung cancer, irrespective of their PD-L1 expression.' Details for the poster presentation:Title: TACTI-004, a Phase 3 trial of Eftilagimod Alfa plus Pembrolizumab (P) + Chemotherapy (C) vs Placebo + P + C in 1st line NSCLC Presenter: Dr. Martin Sebastian, University Hospital of Frankfurt, GermanySession: Clinical Trials in ProgressDate and Time: Tuesday, 9 September 2025 at 10:00 AM CEST The poster will be available on the Posters & Publications section of Immutep's website following the presentation. About Eftilagimod Alfa (efti)Efti is Immutep's proprietary soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. As a first-in-class antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex) Class II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like IFN-ƴ and CXCL10 that further boost the immune system's ability to fight is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with anti-PD-[L]1 immunotherapy and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA). About ImmutepImmutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Australian Investors/Media:Eleanor Pearson, Sodali & Co.+61 2 9066 4071; U.S. Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000; in to access your portfolio

CBA cuts jobs amid AI chatbot rollout
CBA cuts jobs amid AI chatbot rollout

Yahoo

time8 hours ago

  • Yahoo

CBA cuts jobs amid AI chatbot rollout

The Commonwealth Bank of Australia (CBA) has announced the termination of 45 positions within its call centres following the introduction of an AI chatbot designed to handle customer inquiries. The bank has communicated to the impacted employees that consultations are ongoing regarding the job cuts, according to Australian Broadcasting Corporation (ABC). CBA announced it is investing more than A$2bn ($1.30bn) in its operations, including frontline teams and technology services, which may result in "some roles and work can change," reported Reuters. The Finance Sector Union (FSU) has expressed discontent with the decision, advocating for the retraining of affected workers to transition into new roles that utilise AI technology. The CBA stated that it has recruited more than 9,000 individuals in the past year and currently has approximately 670 vacancies within its retail banking services and frontline teams. CBA spokesperson was quoted by ABC as saying: 'To meet the changing needs of our customers, like many organisations, we review the skills we need and how we're organised to deliver the best customer experiences and outcomes. That means some roles and work can change 'Our priority is to explore opportunities for redeployment and to support affected employees with care, dignity and respect throughout the process.' Last week, the CBA informed the FSU about the job reductions, marking a significant moment as it is reportedly the first instance where a bank has attributed job cuts directly to AI implementation. The bank has dismissed claims that these job losses are linked to offshoring, asserting that it plans to provide reskilling opportunities for those affected. A report from CSIRO indicates that 68% of Australian businesses have adopted AI technologies, leading to a notable shift in customer service roles, with many being replaced by chatbots and virtual assistants. "CBA cuts jobs amid AI chatbot rollout" was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store